Atypical antipsychotics for schizophrenia combination therapy and high doses : project protocol

The objectives of this project are to: 1. Identify and appraise the clinical and cost-effectiveness evidence pertaining to use of atypical antipsychotic (AAP) combination and high-dose treatment strategies in the defined population and to develop evidence-based optimal use recommendations for these...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health August 2011, 2011
Series:CADTH optimal use report
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objectives of this project are to: 1. Identify and appraise the clinical and cost-effectiveness evidence pertaining to use of atypical antipsychotic (AAP) combination and high-dose treatment strategies in the defined population and to develop evidence-based optimal use recommendations for these strategies. 2. Identify current utilization of AAP combination and high-dose treatment strategies in Canada. 3. Identify current practices of physicians and patients regarding the use of AAP combination and high-dose treatment strategies in Canada. 4. Identify differences (i.e., the gaps) between optimal prescribing and use of AAP combination and high-dose treatment strategies, as well as actual current utilization and practice. 5. Identify potential barriers to optimal use of AAP combination and high-dose treatment strategies. 6. Identify key messages to encourage optimal prescribing and use of AAP combination and high-dose treatment strategies. 7. Identify effective activities and strategies (interventions), which could be directed toward a variety of audiences such as health and allied health professionals, patients, or government decision-makers, to encourage optimal prescribing and use of AAP combination therapy and high-dose treatment strategies. 8. Develop intervention tools to support optimal prescribing and use of AAP combination therapy and high-dose treatment strategies. 9. Support implementation of tools and evaluation. 10. Develop evaluation mechanisms to measure the impact of intervention tools
Item Description:"This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH)"--T.p. verso
Physical Description:1 PDF file (vi, 46 pages)